Organovo expands board with addition of new director
Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds
Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall
Global M&A By the Numbers: Q1 2022
Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes
Organovo Holdings Inc. appointed David Shapiro as a director, increasing the size of its board to eight members.
Shapiro has served as the chief medical officer of Intercept Pharmaceuticals Inc. since November 2017.
Organovo is a biotech platform company providing 3D bioprint tissues with human functionality.